文献速递肾癌与肾肿瘤

肾癌流行病学:发病率、死亡率、生存、遗传易感性与危险因素

Epidemiology of Renal Cancer: Incidence, Mortality, Survival, Genetic Predisposition, and Risk Factors.
PubMed 文献 · Eur Urol · 2025-07-31

该综述基于国际癌症研究机构全球癌症观察站数据,描述2022年肾癌全球发病与死亡(434,840例新发、155,953例死亡),并预测2050年新发病例增至745,791例(+72%)、死亡增至304,861例(+96%)。5年总生存率按地理区域为40%–75%。文章还汇总了遗传易感基因与可改变及不可改变危险因素,以支持早期检测、选择性基因检测和风险适配的预防筛查策略。

要点

  • 2022年全球肾癌新发434,840例、死亡155,953例,发病与死亡随地理区域和性别而异。
  • 预测2050年新发病例达745,791例(+72%)、死亡达304,861例(+96%)。
  • 5年总生存率按地理区域为40%–75%。

核心结论

  • 当前与预测的肾癌发病和死亡数据可为患者、临床医生和政策制定者提供依据。
  • 肾癌流行病学、遗传易感性和危险因素数据有助于早期检测、指导选择性基因检测并制定风险适配的预防和筛查策略。

研究设计与样本

  • 综述,从国际癌症研究机构全球癌症观察站获取当前及预测的国家层面发病与死亡估计。
  • 发病与死亡分别定义为2022年新发病例数和死亡数,2022至2050年预测基于人口增长和老龄化的推演。
  • 全球指标按地理区域和性别分层评估,生存数据来自国际或国家登记处、系统综述与荟萃分析或原始报告。

主要发现

  • 2022年全球记录肾癌新发434,840例、死亡155,953例,发病与死亡随地理区域和性别变化。
  • 预测2050年新发病例745,791例(+72%)、新发死亡304,861例(+96%)。
  • 5年总生存率按地理区域为40%–75%。

关键数值与推荐

  • 易感基因致病性变异涉及VHL、ELOC、TSC1/2、MET、FLCN、PRDM10、SDHA/B/C/D、MiTF、CDC73、FH、PTEN、BAP1、SMARCB1、CHEK2、MUTYH、BRCA2、ATM和APC。
  • 不可改变危险因素包括性别、地理区域、种族/ ancestry和家族史。
  • 可改变危险因素包括肥胖、胰岛素抵抗/糖尿病、高血压、慢性肾脏病、吸烟、环境暴露和缺乏体育锻炼。

临床怎么用

  • 可利用肾癌流行病学、遗传易感性和危险因素数据促进早期检测。
  • 可辅助选择性基因检测。
  • 可指导风险适配的预防和筛查策略。

局限性

  • 原文未以独立段落列出局限性,仅在结果部分标注「关键发现与局限性」但未展开具体局限内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Renal cancer (RC) is a common malignancy. Its incidence and mortality rates vary by geographic area and sex, and are projected to increase in the future. This review aims to describe global epidemiology of RC examining its incidence, mortality, survival, genetic predisposition, and risk factors. METHODS: We obtained national estimates of the current and projected incidence and mortality from the Global Cancer Observatory of the International Agency for Research on Cancer. Incidence and mortality were defined as the number of new cases and deaths for the year 2022, respectively. Future estimations from 2022 to 2050 were based on the projected population growth and aging. We have assessed all the global metrics and stratified the data according to geographic area and sex. We evaluated survival from international or national registries, systematic reviews and meta-analyses, or original reports. Additionally, we updated epidemiological reviews on genetic predisposition and risk factors. KEY FINDINGS AND LIMITATIONS: Globally, 434,840 individual cases and 155,953 individual deaths were recorded in 2022. Incidence and mortality varied according to geographic area and sex. In total, 745,791 new cases (+72%) and 304,861 (+96%) new deaths are expected in 2050. The 5-yr overall survival rate ranged from 40% to 75% according to geographic area. Pathogenic variants in the alleles, VHL, ELOC, TSC1/2, MET, FLCN, PRDM10, SDHA/B/C/D, MiTF, CDC73, FH, PTEN, BAP1, SMARCB1, CHEK2, MUTYH, BRCA2, ATM, and APC, predispose to RC. Nonmodifiable risk factors include sex, geography, ethnicity/ancestry, and family history. In contrast, modifiable risk factors include obesity, insulin resistance/diabetes, hypertension, chronic kidney disease, smoking, environmental exposure, and lack of physical exercise. CONCLUSIONS AND CLINICAL IMPLICATIONS: The current and projected incidence and mortality rates empower patients, clinicians, and policymakers. Data on RC epidemiology, genetic predisposition, and risk factors may facilitate early detection, aid selective genetic testing, and guide risk-adapted prevention and screening strategies.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Larcher A, Campi R, Bex A, et al. Epidemiology of Renal Cancer: Incidence, Mortality, Survival, Genetic Predisposition, and Risk Factors. Eur Urol. 2025. PMID: 40750496. doi:10.1016/j.eururo.2025.06.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。